2. Academic Validation
  3. Preclinical and first-in-human evaluation of novel androgen receptor-targeted PET imaging in prostate cancer

Preclinical and first-in-human evaluation of novel androgen receptor-targeted PET imaging in prostate cancer

  • Eur J Nucl Med Mol Imaging. 2025 Sep 23. doi: 10.1007/s00259-025-07577-5.
Shuyi Lin # 1 2 3 4,  Xiangwei Wang # 1 2 3 4,  Fangning Wan # 5,  Jianping Zhang 1 2 3 4,  Xiaoping Xu 1 2 3 4,  Bingxin Gu 6 7 8 9,  Zhongyi Yang 10 11 12 13,  Shaoli Song 14 15 16 17
Affiliations

Affiliations

  • 1 Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
  • 2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • 3 Center for Biomedical Imaging, Fudan University, Shanghai, China.
  • 4 Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China.
  • 5 Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • 6 Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China. gubingxin5117@163.com.
  • 7 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. gubingxin5117@163.com.
  • 8 Center for Biomedical Imaging, Fudan University, Shanghai, China. gubingxin5117@163.com.
  • 9 Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China. gubingxin5117@163.com.
  • 10 Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China. yangzhongyi21@163.com.
  • 11 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. yangzhongyi21@163.com.
  • 12 Center for Biomedical Imaging, Fudan University, Shanghai, China. yangzhongyi21@163.com.
  • 13 Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China. yangzhongyi21@163.com.
  • 14 Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China. shaoli-song@163.com.
  • 15 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. shaoli-song@163.com.
  • 16 Center for Biomedical Imaging, Fudan University, Shanghai, China. shaoli-song@163.com.
  • 17 Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China. shaoli-song@163.com.
  • # Contributed equally.
PMID: 40986091 DOI: 10.1007/s00259-025-07577-5
Abstract

Purpose: Activation of Androgen Receptor (AR) signaling is a hallmark of prostate Cancer. Dynamic changes in AR expression exacerbate AR heterogeneity throughout prostate Cancer therapy. This study aims to develop a series of 68Ga-labeled Enzalutamide-based positron emission tomography (PET) tracers for AR imaging.

Methods: [68Ga]Ga-DOTA-FZAR-1, [68Ga]Ga-DOTA-FZAR-2, and [68Ga]Ga-DOTAGA-FZAR-3 were synthesized and the stability was analyzed in vitro. The AR specificity of the three radiotracers was assessed in vitro using AR-negative and AR-positive prostate Cancer cell lines and in vivo using tumor xenograft-bearing mice. Moreover, the first-in-human evaluation of [68Ga]Ga-DOTA-FZAR-2 was conducted in eight patients with prostate Cancer.

Results: [68Ga]Ga-DOTA-FZAR-1, [68Ga]Ga-DOTA-FZAR-2, and [68Ga]Ga-DOTAGA-FZAR-3 were successfully synthesized with a radiochemical purity of more than 99%, and had good stability in vitro. Cellular uptake assays revealed that the radiotracers had the highest, intermediate, and lowest uptake in LNCaP, 22Rv1, and PC-3 cells, respectively, strongly correlating with AR expression levels (P < 0.001). Consistent with cellular uptake, the radiotracers also exhibited a hierarchical uptake pattern (highest to lowest) in tumors of mice bearing LNCaP, 22Rv1 and PC-3 xenografts, respectively. In addition, all three radiotracers were primarily eliminated through the urinary system, as confirmed by ex vivo biodistribution studies. More importantly, first-in-human investigation showed safety and diagnostic value of [68Ga]Ga-DOTA-FZAR-2 in AR-associated prostate Cancer patients.

Conclusion: We developed and validated a series of 68Ga-labeled Enzalutamide-based PET tracers for AR imaging. Initial preclinical and clinical evidence indicate that [68Ga]Ga-DOTA-FZAR-2 enables noninvasive, whole-body, and dynamic monitoring of AR expression in prostate Cancer patients throughout therapy.

Keywords

Androgen receptor; First-in-human; Gallium-68; PET; Prostate cancer.

Figures
Products